Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (GB:0HKF)
LSE:0HKF
Holding GB:0HKF?
Track your performance easily
0HKF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$64.70 - $104.88
Previous Close$91.8
Volume2.07K
Average Volume (3M)1.24K
Market Cap
$4.35B
Enterprise Value$4.21B
Total Cash (Recent Filing)$327.34M
Total Debt (Recent Filing)$191.02M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Mar 03, 2025EPS Estimate
-$0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.54
Shares Outstanding48,462,376
10 Day Avg. Volume1,586
30 Day Avg. Volume1,240
Standard Deviation0.30
R-Squared0.06
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)48.88
Price to Sales (P/S)12.85
Price to Cash Flow (P/CF)-58.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.45
Enterprise Value/Gross Profit17.23
Enterprise Value/Ebitda-14.40
Forecast
1Y Price Target
$133.15Price Target Upside45.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Axsome Therapeutics News
PremiumCompany Announcements
Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic ExpansionsBulls Say, Bears Say
Bulls Say
Market CompetitionThe failure of Relmada Therapeutics' trial removes a potential competitive threat to Auvelity.
Revenue OpportunitiesThe potential label expansion into Alzheimer's disease agitation represents a major incremental revenue opportunity for Auvelity and a source of potential significant stock upside for AXSM shares.
Stock PerformanceThere is potential for a significant stock price increase of up to 40% if the studies achieve a clear positive outcome.
Bears Say
Market CompetitionPotential emerging competition from novel kappa opioid receptor antagonists being developed by Neumora Therapeutics and Johnson & Johnson.
Pipeline Execution RiskIf ADVANCE-2 fails, the stock could decline significantly, raising doubts about AXSM's ability to execute on its pipeline.
Prescription PerformanceWeekly prescription data for Auvelity showed no growth in TRx and NRx, indicating flat performance.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.40% Insiders
18.62% Mutual Funds
40.35% Other Institutional Investors
26.27% Public Companies and
Individual Investors
0HKF FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest share price was $64.70 and its highest was $104.88 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Currently, no data Available
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Mar 03, 2025 which is in 72 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Nov 12, 2024. The company reported -$1.34 earnings per share for the quarter, beating the consensus estimate of -$1.383 by $0.043.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -$0.96.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 48,462,376 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$1.34 in its last earnings report, beating expectations of -$1.383. Following the earnings report the stock price went up 7.791%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Among the largest hedge funds holding Axsome Therapeutics Inc’s share is Fairmount Funds Management Llc. It holds Axsome Therapeutics Inc’s shares valued at 212M.
---
Axsome Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$133.15 (45.05% Upside)
$133.15 (45.05% Upside)
Blogger Sentiment
Bullish
GB:0HKF Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.60%
12-Months-Change
Fundamentals
Return on Equity
-171.61%
Trailing 12-Months
Asset Growth
-6.56%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
---
0HKF Company Deck
---
0HKF Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted robust revenue growth and strong sales performance for key products, alongside significant progress in the pipeline. Despite increased costs and a net loss, the strong cash position and strategic advancements suggest a positive outlook.Read More>---
0HKF Stock 12 Month Forecast
Average Price Target
$133.15
▲(45.05% Upside)
Technical Analysis
Axsome Therapeutics
―
BioMarin Pharmaceutical
―
Innoviva
―
ACADIA Pharmaceuticals
―
Intra-Cellular Therapies
―
Best Analysts Covering 0HKF
1 Year
1 Year Success Rate
15/17 ratings generated profit
1 Year Average Return
+46.49%
assigned a buy rating 25 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +46.49% per trade.
---